12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Wed, 04 Mar 2026 19:41:24 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Set-Cookie: UpalLiveSession=eyJpdiI6Im82RU5kUjA0M3Z2RDBuWkxBSG5cL1JnPT0iLCJ2YWx1ZSI6IjR1dHhURjZ3S0NGR0ZrV1VraXZDNWxkUUFrd0dCRUhQQWxoazBqdGtLMEE5K1NoSjZJdFdDdmozQW1wKzVcL2UxcUFvbHRYWnVpWldhMHl6MVd3VVdhUT09IiwibWFjIjoiMmRlZjA1NzlmNDZjZTQyMmFjNGIzNDJjNzMyZDhkZDk2ZGNkYjExMDQ2MmZkYzA4MTgxYWViMWYyYzg3MWU0NiJ9; expires=Sat, 03-Mar-2029 19:41:24 GMT; Max-Age=94608000; path=/; HttpOnly [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Thu, 05 Mar 2026 19:41:24 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=yNoow%2BqzI7R0skYgYLFYmNlV8UaBXn6BoEwCUUVPAk1MU4rcK%2F8xAq4Bck%2FpTDBaSENw2142P%2BhKNd5P2Myzvbh6ABQHLNJ2S7FQoks%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [21] => Speculation-Rules: "/cdn-cgi/speculation" [22] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [23] => Server-Timing: cfEdge;dur=3,cfOrigin;dur=91 [24] => CF-RAY: 9d735bb5b942c1c8-SIN [25] => alt-svc: h3=":443"; ma=86400 ) 789

 

 

联合药业（DPHARMA，7148，医疗保健组）公布，在截至2019年9月30日止第3财季录得强劲盈利，它将会继续进军特种产品领域，这是其创建利基产品的策略之一。

该集团在一份声明中说：“最近我们已获得注册批准，并推出一种名叫Erysaa的药品，它是红细胞生成素（EPO）。EPO是人体中存在的蛋白质，可根据人体对氧气的需求来调节红细胞的生长。”

所有贫血患者、肾透析急性贫血患者、因抗癌化疗而引起的贫血患者和需要输血的患者均可使用新配方的EPO作为治疗剂。

但是，联合药业指出，最近美元在全球范围内走强带来了挑战，因为它影响到生产和其他营运成本。

“预计将对制造部门利润率以及我们的利润构成压力。”

在截至2019年9月30日止第3财季，该集团的净利润按年从1228万令吉增加20.9％至1486万令吉，而收入则由之前的1亿2584万令吉上升13.5％至1亿4285万令吉。

---

// // // //